|
|
|
|
Health department offers HIV testing
In recognition of National HIV Testing Day Thursday, the La Salle County Health Department is offering the 20-minute Ora Quick rapid HIV test.The goal of the campaign, which is in its 15th year, is to identify people who are HIV...
|
|
|
EGP-437 improves dry eye signs, symptoms in phase II study
Ophthalmology Times E-News Waltham, MAA corticosteroid solution, EGP-437, administered by a proprietary noninvasive ocular drug delivery system showed improvement in signs and symptoms in patients with dry eye syndrome (DES) during a phase...
|
|
|
Free HIV testing to be offered locally
Provided by DIANNE SHIPLEY Sarasota County Health Department   Member agencies of the HIV/AIDS Network of Sarasota County will offer free HIV testing to the public at South County locations through June 30 as part of the 15th annual...
|
|
|
EyeGate Pharma Announces That EGP-437 Improved Signs And Symptoms Of Dry Eye Syndrome In A Phase II Study
Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome ...
|
|
|
EyeGate Pharma announces positive results for phase 2 study of drug, delivery system for dry eye
WALTHAM, Mass.A phase 2 trial has demonstrated the ability of EyeGate Pharma's proprietary corticosteroid solution and ocular drug delivery system to improve the signs and symptoms of dry eye syndrome, according to a press release from...
|
|
|
::: EyeGate Pharma Announces That EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study
- Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome...
|
|
|
EyeGate Pharma Announces That EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study
WALTHAM, MA -- (MARKET WIRE) -- 06/03/09 -- Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and...
|
|
|
EyeGate Pharma Announces That EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study
Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome ...
|
|
|
EyeGate Pharma Announces That EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study
Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES).For the dry eye clinical...
|
|
|
Survivors get on track to triumph over cancer
Annual walkathon expected to raise more than $200K Smaller Text Print Email Share RSS QUEENSBURY -- Margaret Rishel knows cancer all too well.Her mother was diagnosed with it. Her youngest sister, father and mother-and-law each died...
|
|
|
Fovea Reports Positive Results with Prednisporin in Persistent Allergic Conjunctivitis
PARIS, May 4 /PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis....
|
|
|
Cyclosporine for dry eye shows significant improvement in symptoms, according to phase II study
Evry, FrancePhase II of a clinical study examining a formulation of cyclosporine (Cyclokat, Novagali Pharma) has been completed, and results demonstrate statistically significant improvement with signs and symptoms in patients suffering from...
|
|
|
Novagali Pharma Completed a New Phase II With Cyclokat in Dry Eye
/PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine.The results demonstrate statistically...
|
|
|
Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye
EVRY, France, April 15 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat, its formulation of Cyclosporine.The results...
|
